{"name":"Juan J Badimon","slug":"juan-j-badimon","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Cardiovascular","slug":"cardiovascular","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Clopidogrel + ASA + Bivalirudin","genericName":"Clopidogrel + ASA + Bivalirudin","slug":"clopidogrel-asa-bivalirudin","indication":"Acute coronary syndrome with percutaneous coronary intervention","status":"marketed"},{"name":"Ticagrelor + ASA + Bivalirudin","genericName":"Ticagrelor + ASA + Bivalirudin","slug":"ticagrelor-asa-bivalirudin","indication":"Acute coronary syndrome with percutaneous coronary intervention","status":"marketed"}]}],"pipeline":[{"name":"Clopidogrel + ASA + Bivalirudin","genericName":"Clopidogrel + ASA + Bivalirudin","slug":"clopidogrel-asa-bivalirudin","phase":"marketed","mechanism":"This triple antiplatelet and anticoagulant combination inhibits platelet aggregation through multiple pathways while simultaneously blocking thrombin generation to prevent thrombotic events.","indications":["Acute coronary syndrome with percutaneous coronary intervention","Prevention of stent thrombosis"],"catalyst":""},{"name":"Ticagrelor + ASA + Bivalirudin","genericName":"Ticagrelor + ASA + Bivalirudin","slug":"ticagrelor-asa-bivalirudin","phase":"marketed","mechanism":"This combination uses ticagrelor and aspirin to inhibit platelet aggregation via P2Y12 and COX-1 pathways, while bivalirudin provides direct thrombin inhibition to prevent thrombotic events.","indications":["Acute coronary syndrome with percutaneous coronary intervention","Prevention of stent thrombosis and recurrent ischemic events"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQeXFoVFAzQ2JhbUxjWk5SY1lfQktXV3BnNGhlTmFrbi0yNGo5YUp4VHZRdFVoOFJ3Vk1XLW41aGhjRDdhQ1VVUTFYRmhYU0RZSEpFaVV1WjlidFBqakpxbHh0ekM4LVh2YjJXTDBVNTVPZXdTNjdCVm12UTFpM2M1ZXg0azJQelFFdzlqQg?oc=5","date":"2025-11-24","type":"pipeline","source":"Yahoo Finance","summary":"Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development - Yahoo Finance","headline":"Lexicon Pharmaceuticals, Inc. (LXRX) Makes Progress in Product Pipeline Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOQVVTcndwQ3ZqT3ByLU00ZmRsTXUzNEFKTVhaZGtzM2paTTZVX2s4Qlk0QnhaZlNYOEFZbVFKbTJFOFJsdDlSLTZ6eWkwTF9oNnp3QXZyUnEyU3hDYWhFVnR5bHQwVHhNNUdqR2w1dHg5bWpSNEZiQ3FyQnJPOWpsbzZab09OZVJOZy1VZVo2ajI?oc=5","date":"2025-11-23","type":"deal","source":"Insider Monkey","summary":"10 Fastest Growing Penny Stocks to Buy Now - Insider Monkey","headline":"10 Fastest Growing Penny Stocks to Buy Now","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxNYWY1X0ZHNG1BSlRPSVdNbTJMVUZtTlphVHRfd2k4T2t2dTIxb0N6VlFiVUxDQndFbHRGekk5Ylp0cmpnNEFRa2JXbHJVdTZoalpkZ19sOFlxYk4yZWdKaklyN0V2T1J1emRPY0VVS2dIZzdGNzctQXRNRWhndVlucHF1NzNzYWluX0d5RDltdlRLX3ZpMVZoMkNLNURtUnZESndOT0prdVBZQ0s0eldwWU5wOTJTb2oxaDRwU2hMVFVDSUQ5YXowV0xDQ3lOOGRpOTRtSGZwYjBZZWJOcDV5TkRmYW53azdaRUdMTnh0dml2Zw?oc=5","date":"2025-11-08","type":"trial","source":"Quiver Quantitative","summary":"Lexicon Pharmaceuticals Reveals Positive Clinical Data for Sotagliflozin in Heart Failure Patients Without Diabetes at AHA 2025 - Quiver Quantitative","headline":"Lexicon Pharmaceuticals Reveals Positive Clinical Data for Sotagliflozin in Heart Failure Patients Without Diabetes at A","sentiment":"negative"},{"url":"https://news.google.com/rss/articles/CBMidEFVX3lxTE9Yck93MGlSd3R6allwQndUSXlJX0hkbzZGVl9SSWpydkVmQjFHRUpiVUpSZ0ZQS3lkWkcyTlBWVDdaaklITG50Nk1OT3M5Y1Eya0hTN0xfRkExRXp4S2dMd0FvMWtZZU04X1o0bS01bWZha2dx?oc=5","date":"2023-04-12","type":"pipeline","source":"ahajournals.org","summary":"Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction - ahajournals.org","headline":"Cardioprotective Effect of Empagliflozin and Circulating Ketone Bodies During Acute Myocardial Infarction","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"marketed":2},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}